In the ELAIN study, a fixed NGAL threshold was used as an inclusion criterion, defining the need for early KRT as AKI KDIGO stage 2 and plasma NGAL > 150 ng/mL and delayed KRT as AKI stage 3. This evidence concerns the gene LCN2 and acute kidney injury.